TrianglePUBLICATIONS · 34724226
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Int J Cancer
- Publication date
- 2022 Mar 15
- First author
- Cousin S
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Cousin S
- type
- Author
- name
- Blay JY
- type
- Author
- name
- Garcia IB
- type
- Author
- name
- de Bono JS
- type
- Author
- name
- Le Tourneau C
- type
- Author
- name
- Moreno V
- type
- Author
- name
- Trigo J
- type
- Author
- name
- Hann CL
- type
- Author
- name
- Azad AA
- type
- Author
- name
- Im SA
- type
- Author
- name
- Cassier PA
- type
- Author
- name
- French CA
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Cousin S
- type
- Author
- name
- Blay JY
- type
- Author
- name
- Garcia IB
- type
- Author
- name
- de Bono JS
- type
- Author
- name
- Le Tourneau C
- type
- Author
- name
- Moreno V
- type
- Author
- name
- Trigo J
- type
- Author
- name
- Hann CL
- type
- Author
- name
- Azad AA
- type
- Author
- name
- Im SA
- type
- Author
- name
- Cassier PA
- type
- Author
- name
- French CA
- type
- Author
- bibliography ids
- nci-bib-2220e315455d6e2d83a47735
- book metadata
- content sha256
- b9ef56b810c0aef3b54e21339ac73c651db5d22c3a88b36305b78c9eaa87106e
- document type
- citation
- dois
- 10.1002/ijc.33861
- electronic publication date
- display
- 2021 Nov 26
- precision
- day
- year
- 2021
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:34724226
- immutable id
- pubmed:34724226@b9ef56b810c0aef3b54e21339ac73c651db5d22c3a88b36305b78c9eaa87106e
- journal
- abbreviation
- Int J Cancer
- issn electronic
- 1097-0215
- issn print
- 0020-7136
- issue
- 6
- name
- International journal of cancer
- nlm unique id
- 0042124
- pages
- 993-1006
- volume
- 150
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 34724226
- provenance
- batch id
- 3f4d1914d2afe41e9e70
- provider
- NCBI PubMed ESummary
- record sha256
- 23a8860d0b3cc2c810c67b37343d46ab8d3f7a9c258567a948148038c2d10082
- response sha256
- 0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
- retrieved at
- 2026-09-09T23:48:06.522634+00:00
- publication date
- display
- 2022 Mar 15
- precision
- day
- year
- 2022
- publication types
- Clinical Trial, Phase I
- Clinical Trial, Phase II
- Journal Article
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
Preserved source evidence · Not medical advice